Global Omalizumab Monoclonal Antibody Biosimilars Supply, Demand and Key Producers, 2026-2032
The global Omalizumab Monoclonal Antibody Biosimilars market size is expected to reach $ 606 million by 2032, rising at a market growth of 11.0% CAGR during the forecast period (2026-2032).
In 2025, global Omalizumab Monoclonal Antibody Biosimilars production reached approximately 909 k doses, with an average global market price of around US$ 319 per dose. Gross margin is about 43%. The cost is 182 usd, the production is 1200 k doses. Omalizumab monoclonal antibody biosimilar is a medication used to treat asthma, nasal polyps, and urticaria. Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Unlike an ordinary anti-IgE antibody, it does not bind to IgE that is already bound by the high affinity IgE receptor (Fc?RI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells.
The market is entering a rapid commercialization stage
As the first omalizumab biosimilars gain approval in major markets such as Europe and the United States, the market is shifting from development and regulatory preparation to commercialization and competition. More biosimilar manufacturers are expected to enter the market, accelerating adoption and increasing competition.
Price competition will become increasingly important
As more omalizumab biosimilars are launched, price competition is expected to intensify. Lower treatment costs will improve patient access and encourage hospitals, insurers, and healthcare systems to promote biosimilar substitution over the original branded drug.
Interchangeability will become a key competitive advantage
In the United States, interchangeability status is likely to become an important factor influencing market share. Biosimilars with interchangeable designation may gain stronger acceptance from pharmacies, payers, and physicians because they can be substituted more easily for the original product.
More dosage forms and specifications will be introduced
Manufacturers are expected to launch additional dosage strengths, pre-filled syringes, auto-injectors, and patient-friendly packaging formats. Competition will increasingly depend on product portfolios, ease of administration, and compatibility with existing treatment practices.
Expansion of indications will increase long-term market potential
As the original omalizumab product continues to gain approvals for new indications such as food allergy, nasal polyps, and other IgE-mediated diseases, biosimilars are also expected to benefit from a larger addressable market in the future.
This report studies the global Omalizumab Monoclonal Antibody Biosimilars production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Omalizumab Monoclonal Antibody Biosimilars and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Omalizumab Monoclonal Antibody Biosimilars that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Omalizumab Monoclonal Antibody Biosimilars total production and demand, 2021-2032, (K Dose)
Global Omalizumab Monoclonal Antibody Biosimilars total production value, 2021-2032, (USD Million)
Global Omalizumab Monoclonal Antibody Biosimilars production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Dose), (based on production site)
Global Omalizumab Monoclonal Antibody Biosimilars consumption by region & country, CAGR, 2021-2032 & (K Dose)
U.S. VS China: Omalizumab Monoclonal Antibody Biosimilars domestic production, consumption, key domestic manufacturers and share
Global Omalizumab Monoclonal Antibody Biosimilars production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Dose)
Global Omalizumab Monoclonal Antibody Biosimilars production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Dose)
Global Omalizumab Monoclonal Antibody Biosimilars production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Dose)
This report profiles key players in the global Omalizumab Monoclonal Antibody Biosimilars market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Novartis, Glenmark Pharmaceuticals, Selexis, Generium, CuraTeQ, Celltrion Healthcare, Alvotech, BiosanaPharma, Mabpharm, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Omalizumab Monoclonal Antibody Biosimilars market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Dose) and average price (US$/Dose) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Omalizumab Monoclonal Antibody Biosimilars Market, By Region:
1. How big is the global Omalizumab Monoclonal Antibody Biosimilars market?
2. What is the demand of the global Omalizumab Monoclonal Antibody Biosimilars market?
3. What is the year over year growth of the global Omalizumab Monoclonal Antibody Biosimilars market?
4. What is the production and production value of the global Omalizumab Monoclonal Antibody Biosimilars market?
5. Who are the key producers in the global Omalizumab Monoclonal Antibody Biosimilars market?
6. What are the growth factors driving the market demand?
In 2025, global Omalizumab Monoclonal Antibody Biosimilars production reached approximately 909 k doses, with an average global market price of around US$ 319 per dose. Gross margin is about 43%. The cost is 182 usd, the production is 1200 k doses. Omalizumab monoclonal antibody biosimilar is a medication used to treat asthma, nasal polyps, and urticaria. Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) in the blood and interstitial fluid and to membrane-bound form of IgE (mIgE) on the surface of mIgE-expressing B lymphocytes. Unlike an ordinary anti-IgE antibody, it does not bind to IgE that is already bound by the high affinity IgE receptor (Fc?RI) on the surface of mast cells, basophils, and antigen-presenting dendritic cells.
The market is entering a rapid commercialization stage
As the first omalizumab biosimilars gain approval in major markets such as Europe and the United States, the market is shifting from development and regulatory preparation to commercialization and competition. More biosimilar manufacturers are expected to enter the market, accelerating adoption and increasing competition.
Price competition will become increasingly important
As more omalizumab biosimilars are launched, price competition is expected to intensify. Lower treatment costs will improve patient access and encourage hospitals, insurers, and healthcare systems to promote biosimilar substitution over the original branded drug.
Interchangeability will become a key competitive advantage
In the United States, interchangeability status is likely to become an important factor influencing market share. Biosimilars with interchangeable designation may gain stronger acceptance from pharmacies, payers, and physicians because they can be substituted more easily for the original product.
More dosage forms and specifications will be introduced
Manufacturers are expected to launch additional dosage strengths, pre-filled syringes, auto-injectors, and patient-friendly packaging formats. Competition will increasingly depend on product portfolios, ease of administration, and compatibility with existing treatment practices.
Expansion of indications will increase long-term market potential
As the original omalizumab product continues to gain approvals for new indications such as food allergy, nasal polyps, and other IgE-mediated diseases, biosimilars are also expected to benefit from a larger addressable market in the future.
This report studies the global Omalizumab Monoclonal Antibody Biosimilars production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Omalizumab Monoclonal Antibody Biosimilars and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Omalizumab Monoclonal Antibody Biosimilars that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Omalizumab Monoclonal Antibody Biosimilars total production and demand, 2021-2032, (K Dose)
Global Omalizumab Monoclonal Antibody Biosimilars total production value, 2021-2032, (USD Million)
Global Omalizumab Monoclonal Antibody Biosimilars production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (K Dose), (based on production site)
Global Omalizumab Monoclonal Antibody Biosimilars consumption by region & country, CAGR, 2021-2032 & (K Dose)
U.S. VS China: Omalizumab Monoclonal Antibody Biosimilars domestic production, consumption, key domestic manufacturers and share
Global Omalizumab Monoclonal Antibody Biosimilars production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (K Dose)
Global Omalizumab Monoclonal Antibody Biosimilars production by Type, production, value, CAGR, 2021-2032, (USD Million) & (K Dose)
Global Omalizumab Monoclonal Antibody Biosimilars production by Application, production, value, CAGR, 2021-2032, (USD Million) & (K Dose)
This report profiles key players in the global Omalizumab Monoclonal Antibody Biosimilars market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Novartis, Glenmark Pharmaceuticals, Selexis, Generium, CuraTeQ, Celltrion Healthcare, Alvotech, BiosanaPharma, Mabpharm, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Omalizumab Monoclonal Antibody Biosimilars market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Dose) and average price (US$/Dose) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Omalizumab Monoclonal Antibody Biosimilars Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- 150 mg/mL
- 75 mg/0.5 mL
- For Adults
- For Teenagers
- For Children
- Every 2 Weeks
- Every 4 Weeks
- Individualized Dosing Regimen
- Persistent Asthma
- Nasal Polyps
- Chronic Idiopathic Urticaria
- Roche
- Novartis
- Glenmark Pharmaceuticals
- Selexis
- Generium
- CuraTeQ
- Celltrion Healthcare
- Alvotech
- BiosanaPharma
- Mabpharm
- CSPC Pharmaceutical Group
- Biomabs
- HisunPharm
1. How big is the global Omalizumab Monoclonal Antibody Biosimilars market?
2. What is the demand of the global Omalizumab Monoclonal Antibody Biosimilars market?
3. What is the year over year growth of the global Omalizumab Monoclonal Antibody Biosimilars market?
4. What is the production and production value of the global Omalizumab Monoclonal Antibody Biosimilars market?
5. Who are the key producers in the global Omalizumab Monoclonal Antibody Biosimilars market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Omalizumab Monoclonal Antibody Biosimilars Introduction
1.2 World Omalizumab Monoclonal Antibody Biosimilars Supply & Forecast
1.2.1 World Omalizumab Monoclonal Antibody Biosimilars Production Value (2021 & 2025 & 2032)
1.2.2 World Omalizumab Monoclonal Antibody Biosimilars Production (2021-2032)
1.2.3 World Omalizumab Monoclonal Antibody Biosimilars Pricing Trends (2021-2032)
1.3 World Omalizumab Monoclonal Antibody Biosimilars Production by Region (Based on Production Site)
1.3.1 World Omalizumab Monoclonal Antibody Biosimilars Production Value by Region (2021-2032)
1.3.2 World Omalizumab Monoclonal Antibody Biosimilars Production by Region (2021-2032)
1.3.3 World Omalizumab Monoclonal Antibody Biosimilars Average Price by Region (2021-2032)
1.3.4 North America Omalizumab Monoclonal Antibody Biosimilars Production (2021-2032)
1.3.5 Europe Omalizumab Monoclonal Antibody Biosimilars Production (2021-2032)
1.3.6 China Omalizumab Monoclonal Antibody Biosimilars Production (2021-2032)
1.3.7 Japan Omalizumab Monoclonal Antibody Biosimilars Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Omalizumab Monoclonal Antibody Biosimilars Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Omalizumab Monoclonal Antibody Biosimilars Major Market Trends
2 DEMAND SUMMARY
2.1 World Omalizumab Monoclonal Antibody Biosimilars Demand (2021-2032)
2.2 World Omalizumab Monoclonal Antibody Biosimilars Consumption by Region
2.2.1 World Omalizumab Monoclonal Antibody Biosimilars Consumption by Region (2021-2026)
2.2.2 World Omalizumab Monoclonal Antibody Biosimilars Consumption Forecast by Region (2027-2032)
2.3 United States Omalizumab Monoclonal Antibody Biosimilars Consumption (2021-2032)
2.4 China Omalizumab Monoclonal Antibody Biosimilars Consumption (2021-2032)
2.5 Europe Omalizumab Monoclonal Antibody Biosimilars Consumption (2021-2032)
2.6 Japan Omalizumab Monoclonal Antibody Biosimilars Consumption (2021-2032)
2.7 South Korea Omalizumab Monoclonal Antibody Biosimilars Consumption (2021-2032)
2.8 ASEAN Omalizumab Monoclonal Antibody Biosimilars Consumption (2021-2032)
2.9 India Omalizumab Monoclonal Antibody Biosimilars Consumption (2021-2032)
3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Omalizumab Monoclonal Antibody Biosimilars Production Value by Manufacturer (2021-2026)
3.2 World Omalizumab Monoclonal Antibody Biosimilars Production by Manufacturer (2021-2026)
3.3 World Omalizumab Monoclonal Antibody Biosimilars Average Price by Manufacturer (2021-2026)
3.4 Omalizumab Monoclonal Antibody Biosimilars Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Omalizumab Monoclonal Antibody Biosimilars Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Omalizumab Monoclonal Antibody Biosimilars in 2025
3.5.3 Global Concentration Ratios (CR8) for Omalizumab Monoclonal Antibody Biosimilars in 2025
3.6 Omalizumab Monoclonal Antibody Biosimilars Market: Overall Company Footprint Analysis
3.6.1 Omalizumab Monoclonal Antibody Biosimilars Market: Region Footprint
3.6.2 Omalizumab Monoclonal Antibody Biosimilars Market: Company Product Type Footprint
3.6.3 Omalizumab Monoclonal Antibody Biosimilars Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Omalizumab Monoclonal Antibody Biosimilars Production Value Comparison
4.1.1 United States VS China: Omalizumab Monoclonal Antibody Biosimilars Production Value Comparison (2021 & 2025 & 2032)
4.1.2 United States VS China: Omalizumab Monoclonal Antibody Biosimilars Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: Omalizumab Monoclonal Antibody Biosimilars Production Comparison
4.2.1 United States VS China: Omalizumab Monoclonal Antibody Biosimilars Production Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Omalizumab Monoclonal Antibody Biosimilars Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: Omalizumab Monoclonal Antibody Biosimilars Consumption Comparison
4.3.1 United States VS China: Omalizumab Monoclonal Antibody Biosimilars Consumption Comparison (2021 & 2025 & 2032)
4.3.2 United States VS China: Omalizumab Monoclonal Antibody Biosimilars Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based Omalizumab Monoclonal Antibody Biosimilars Manufacturers and Market Share, 2021-2026
4.4.1 United States Based Omalizumab Monoclonal Antibody Biosimilars Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Omalizumab Monoclonal Antibody Biosimilars Production Value (2021-2026)
4.4.3 United States Based Manufacturers Omalizumab Monoclonal Antibody Biosimilars Production (2021-2026)
4.5 China Based Omalizumab Monoclonal Antibody Biosimilars Manufacturers and Market Share
4.5.1 China Based Omalizumab Monoclonal Antibody Biosimilars Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Omalizumab Monoclonal Antibody Biosimilars Production Value (2021-2026)
4.5.3 China Based Manufacturers Omalizumab Monoclonal Antibody Biosimilars Production (2021-2026)
4.6 Rest of World Based Omalizumab Monoclonal Antibody Biosimilars Manufacturers and Market Share, 2021-2026
4.6.1 Rest of World Based Omalizumab Monoclonal Antibody Biosimilars Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Omalizumab Monoclonal Antibody Biosimilars Production Value (2021-2026)
4.6.3 Rest of World Based Manufacturers Omalizumab Monoclonal Antibody Biosimilars Production (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Omalizumab Monoclonal Antibody Biosimilars Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 150 mg/mL
5.2.2 75 mg/0.5 mL
5.3 Market Segment by Type
5.3.1 World Omalizumab Monoclonal Antibody Biosimilars Production by Type (2021-2032)
5.3.2 World Omalizumab Monoclonal Antibody Biosimilars Production Value by Type (2021-2032)
5.3.3 World Omalizumab Monoclonal Antibody Biosimilars Average Price by Type (2021-2032)
6 MARKET ANALYSIS BY AGE
6.1 World Omalizumab Monoclonal Antibody Biosimilars Market Size Overview by Age: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Age
6.2.1 For Adults
6.2.2 For Teenagers
6.2.3 For Children
6.3 Market Segment by Age
6.3.1 World Omalizumab Monoclonal Antibody Biosimilars Production by Age (2021-2032)
6.3.2 World Omalizumab Monoclonal Antibody Biosimilars Production Value by Age (2021-2032)
6.3.3 World Omalizumab Monoclonal Antibody Biosimilars Average Price by Age (2021-2032)
7 MARKET ANALYSIS BY FREQUENCY
7.1 World Omalizumab Monoclonal Antibody Biosimilars Market Size Overview by Frequency: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Frequency
7.2.1 Every 2 Weeks
7.2.2 Every 4 Weeks
7.2.3 Individualized Dosing Regimen
7.3 Market Segment by Frequency
7.3.1 World Omalizumab Monoclonal Antibody Biosimilars Production by Frequency (2021-2032)
7.3.2 World Omalizumab Monoclonal Antibody Biosimilars Production Value by Frequency (2021-2032)
7.3.3 World Omalizumab Monoclonal Antibody Biosimilars Average Price by Frequency (2021-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Omalizumab Monoclonal Antibody Biosimilars Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Persistent Asthma
8.2.2 Nasal Polyps
8.2.3 Chronic Idiopathic Urticaria
8.3 Market Segment by Application
8.3.1 World Omalizumab Monoclonal Antibody Biosimilars Production by Application (2021-2032)
8.3.2 World Omalizumab Monoclonal Antibody Biosimilars Production Value by Application (2021-2032)
8.3.3 World Omalizumab Monoclonal Antibody Biosimilars Average Price by Application (2021-2032)
9 COMPANY PROFILES
9.1 Roche
9.1.1 Roche Details
9.1.2 Roche Major Business
9.1.3 Roche Omalizumab Monoclonal Antibody Biosimilars Product and Services
9.1.4 Roche Omalizumab Monoclonal Antibody Biosimilars Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.1.5 Roche Recent Developments/Updates
9.1.6 Roche Competitive Strengths & Weaknesses
9.2 Novartis
9.2.1 Novartis Details
9.2.2 Novartis Major Business
9.2.3 Novartis Omalizumab Monoclonal Antibody Biosimilars Product and Services
9.2.4 Novartis Omalizumab Monoclonal Antibody Biosimilars Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.2.5 Novartis Recent Developments/Updates
9.2.6 Novartis Competitive Strengths & Weaknesses
9.3 Glenmark Pharmaceuticals
9.3.1 Glenmark Pharmaceuticals Details
9.3.2 Glenmark Pharmaceuticals Major Business
9.3.3 Glenmark Pharmaceuticals Omalizumab Monoclonal Antibody Biosimilars Product and Services
9.3.4 Glenmark Pharmaceuticals Omalizumab Monoclonal Antibody Biosimilars Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.3.5 Glenmark Pharmaceuticals Recent Developments/Updates
9.3.6 Glenmark Pharmaceuticals Competitive Strengths & Weaknesses
9.4 Selexis
9.4.1 Selexis Details
9.4.2 Selexis Major Business
9.4.3 Selexis Omalizumab Monoclonal Antibody Biosimilars Product and Services
9.4.4 Selexis Omalizumab Monoclonal Antibody Biosimilars Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.4.5 Selexis Recent Developments/Updates
9.4.6 Selexis Competitive Strengths & Weaknesses
9.5 Generium
9.5.1 Generium Details
9.5.2 Generium Major Business
9.5.3 Generium Omalizumab Monoclonal Antibody Biosimilars Product and Services
9.5.4 Generium Omalizumab Monoclonal Antibody Biosimilars Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.5.5 Generium Recent Developments/Updates
9.5.6 Generium Competitive Strengths & Weaknesses
9.6 CuraTeQ
9.6.1 CuraTeQ Details
9.6.2 CuraTeQ Major Business
9.6.3 CuraTeQ Omalizumab Monoclonal Antibody Biosimilars Product and Services
9.6.4 CuraTeQ Omalizumab Monoclonal Antibody Biosimilars Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.6.5 CuraTeQ Recent Developments/Updates
9.6.6 CuraTeQ Competitive Strengths & Weaknesses
9.7 Celltrion Healthcare
9.7.1 Celltrion Healthcare Details
9.7.2 Celltrion Healthcare Major Business
9.7.3 Celltrion Healthcare Omalizumab Monoclonal Antibody Biosimilars Product and Services
9.7.4 Celltrion Healthcare Omalizumab Monoclonal Antibody Biosimilars Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.7.5 Celltrion Healthcare Recent Developments/Updates
9.7.6 Celltrion Healthcare Competitive Strengths & Weaknesses
9.8 Alvotech
9.8.1 Alvotech Details
9.8.2 Alvotech Major Business
9.8.3 Alvotech Omalizumab Monoclonal Antibody Biosimilars Product and Services
9.8.4 Alvotech Omalizumab Monoclonal Antibody Biosimilars Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.8.5 Alvotech Recent Developments/Updates
9.8.6 Alvotech Competitive Strengths & Weaknesses
9.9 BiosanaPharma
9.9.1 BiosanaPharma Details
9.9.2 BiosanaPharma Major Business
9.9.3 BiosanaPharma Omalizumab Monoclonal Antibody Biosimilars Product and Services
9.9.4 BiosanaPharma Omalizumab Monoclonal Antibody Biosimilars Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.9.5 BiosanaPharma Recent Developments/Updates
9.9.6 BiosanaPharma Competitive Strengths & Weaknesses
9.10 Mabpharm
9.10.1 Mabpharm Details
9.10.2 Mabpharm Major Business
9.10.3 Mabpharm Omalizumab Monoclonal Antibody Biosimilars Product and Services
9.10.4 Mabpharm Omalizumab Monoclonal Antibody Biosimilars Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.10.5 Mabpharm Recent Developments/Updates
9.10.6 Mabpharm Competitive Strengths & Weaknesses
9.11 CSPC Pharmaceutical Group
9.11.1 CSPC Pharmaceutical Group Details
9.11.2 CSPC Pharmaceutical Group Major Business
9.11.3 CSPC Pharmaceutical Group Omalizumab Monoclonal Antibody Biosimilars Product and Services
9.11.4 CSPC Pharmaceutical Group Omalizumab Monoclonal Antibody Biosimilars Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.11.5 CSPC Pharmaceutical Group Recent Developments/Updates
9.11.6 CSPC Pharmaceutical Group Competitive Strengths & Weaknesses
9.12 Biomabs
9.12.1 Biomabs Details
9.12.2 Biomabs Major Business
9.12.3 Biomabs Omalizumab Monoclonal Antibody Biosimilars Product and Services
9.12.4 Biomabs Omalizumab Monoclonal Antibody Biosimilars Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.12.5 Biomabs Recent Developments/Updates
9.12.6 Biomabs Competitive Strengths & Weaknesses
9.13 HisunPharm
9.13.1 HisunPharm Details
9.13.2 HisunPharm Major Business
9.13.3 HisunPharm Omalizumab Monoclonal Antibody Biosimilars Product and Services
9.13.4 HisunPharm Omalizumab Monoclonal Antibody Biosimilars Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.13.5 HisunPharm Recent Developments/Updates
9.13.6 HisunPharm Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Omalizumab Monoclonal Antibody Biosimilars Industry Chain
10.2 Omalizumab Monoclonal Antibody Biosimilars Upstream Analysis
10.2.1 Omalizumab Monoclonal Antibody Biosimilars Core Raw Materials
10.2.2 Main Manufacturers of Omalizumab Monoclonal Antibody Biosimilars Core Raw Materials
10.3 Midstream Analysis
10.4 Downstream Analysis
10.5 Omalizumab Monoclonal Antibody Biosimilars Production Mode
10.6 Omalizumab Monoclonal Antibody Biosimilars Procurement Model
10.7 Omalizumab Monoclonal Antibody Biosimilars Industry Sales Model and Sales Channels
10.7.1 Omalizumab Monoclonal Antibody Biosimilars Sales Model
10.7.2 Omalizumab Monoclonal Antibody Biosimilars Typical Distributors
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
1.1 Omalizumab Monoclonal Antibody Biosimilars Introduction
1.2 World Omalizumab Monoclonal Antibody Biosimilars Supply & Forecast
1.2.1 World Omalizumab Monoclonal Antibody Biosimilars Production Value (2021 & 2025 & 2032)
1.2.2 World Omalizumab Monoclonal Antibody Biosimilars Production (2021-2032)
1.2.3 World Omalizumab Monoclonal Antibody Biosimilars Pricing Trends (2021-2032)
1.3 World Omalizumab Monoclonal Antibody Biosimilars Production by Region (Based on Production Site)
1.3.1 World Omalizumab Monoclonal Antibody Biosimilars Production Value by Region (2021-2032)
1.3.2 World Omalizumab Monoclonal Antibody Biosimilars Production by Region (2021-2032)
1.3.3 World Omalizumab Monoclonal Antibody Biosimilars Average Price by Region (2021-2032)
1.3.4 North America Omalizumab Monoclonal Antibody Biosimilars Production (2021-2032)
1.3.5 Europe Omalizumab Monoclonal Antibody Biosimilars Production (2021-2032)
1.3.6 China Omalizumab Monoclonal Antibody Biosimilars Production (2021-2032)
1.3.7 Japan Omalizumab Monoclonal Antibody Biosimilars Production (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Omalizumab Monoclonal Antibody Biosimilars Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Omalizumab Monoclonal Antibody Biosimilars Major Market Trends
2 DEMAND SUMMARY
2.1 World Omalizumab Monoclonal Antibody Biosimilars Demand (2021-2032)
2.2 World Omalizumab Monoclonal Antibody Biosimilars Consumption by Region
2.2.1 World Omalizumab Monoclonal Antibody Biosimilars Consumption by Region (2021-2026)
2.2.2 World Omalizumab Monoclonal Antibody Biosimilars Consumption Forecast by Region (2027-2032)
2.3 United States Omalizumab Monoclonal Antibody Biosimilars Consumption (2021-2032)
2.4 China Omalizumab Monoclonal Antibody Biosimilars Consumption (2021-2032)
2.5 Europe Omalizumab Monoclonal Antibody Biosimilars Consumption (2021-2032)
2.6 Japan Omalizumab Monoclonal Antibody Biosimilars Consumption (2021-2032)
2.7 South Korea Omalizumab Monoclonal Antibody Biosimilars Consumption (2021-2032)
2.8 ASEAN Omalizumab Monoclonal Antibody Biosimilars Consumption (2021-2032)
2.9 India Omalizumab Monoclonal Antibody Biosimilars Consumption (2021-2032)
3 WORLD MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Omalizumab Monoclonal Antibody Biosimilars Production Value by Manufacturer (2021-2026)
3.2 World Omalizumab Monoclonal Antibody Biosimilars Production by Manufacturer (2021-2026)
3.3 World Omalizumab Monoclonal Antibody Biosimilars Average Price by Manufacturer (2021-2026)
3.4 Omalizumab Monoclonal Antibody Biosimilars Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Omalizumab Monoclonal Antibody Biosimilars Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Omalizumab Monoclonal Antibody Biosimilars in 2025
3.5.3 Global Concentration Ratios (CR8) for Omalizumab Monoclonal Antibody Biosimilars in 2025
3.6 Omalizumab Monoclonal Antibody Biosimilars Market: Overall Company Footprint Analysis
3.6.1 Omalizumab Monoclonal Antibody Biosimilars Market: Region Footprint
3.6.2 Omalizumab Monoclonal Antibody Biosimilars Market: Company Product Type Footprint
3.6.3 Omalizumab Monoclonal Antibody Biosimilars Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Omalizumab Monoclonal Antibody Biosimilars Production Value Comparison
4.1.1 United States VS China: Omalizumab Monoclonal Antibody Biosimilars Production Value Comparison (2021 & 2025 & 2032)
4.1.2 United States VS China: Omalizumab Monoclonal Antibody Biosimilars Production Value Market Share Comparison (2021 & 2025 & 2032)
4.2 United States VS China: Omalizumab Monoclonal Antibody Biosimilars Production Comparison
4.2.1 United States VS China: Omalizumab Monoclonal Antibody Biosimilars Production Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Omalizumab Monoclonal Antibody Biosimilars Production Market Share Comparison (2021 & 2025 & 2032)
4.3 United States VS China: Omalizumab Monoclonal Antibody Biosimilars Consumption Comparison
4.3.1 United States VS China: Omalizumab Monoclonal Antibody Biosimilars Consumption Comparison (2021 & 2025 & 2032)
4.3.2 United States VS China: Omalizumab Monoclonal Antibody Biosimilars Consumption Market Share Comparison (2021 & 2025 & 2032)
4.4 United States Based Omalizumab Monoclonal Antibody Biosimilars Manufacturers and Market Share, 2021-2026
4.4.1 United States Based Omalizumab Monoclonal Antibody Biosimilars Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Omalizumab Monoclonal Antibody Biosimilars Production Value (2021-2026)
4.4.3 United States Based Manufacturers Omalizumab Monoclonal Antibody Biosimilars Production (2021-2026)
4.5 China Based Omalizumab Monoclonal Antibody Biosimilars Manufacturers and Market Share
4.5.1 China Based Omalizumab Monoclonal Antibody Biosimilars Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Omalizumab Monoclonal Antibody Biosimilars Production Value (2021-2026)
4.5.3 China Based Manufacturers Omalizumab Monoclonal Antibody Biosimilars Production (2021-2026)
4.6 Rest of World Based Omalizumab Monoclonal Antibody Biosimilars Manufacturers and Market Share, 2021-2026
4.6.1 Rest of World Based Omalizumab Monoclonal Antibody Biosimilars Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Omalizumab Monoclonal Antibody Biosimilars Production Value (2021-2026)
4.6.3 Rest of World Based Manufacturers Omalizumab Monoclonal Antibody Biosimilars Production (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Omalizumab Monoclonal Antibody Biosimilars Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 150 mg/mL
5.2.2 75 mg/0.5 mL
5.3 Market Segment by Type
5.3.1 World Omalizumab Monoclonal Antibody Biosimilars Production by Type (2021-2032)
5.3.2 World Omalizumab Monoclonal Antibody Biosimilars Production Value by Type (2021-2032)
5.3.3 World Omalizumab Monoclonal Antibody Biosimilars Average Price by Type (2021-2032)
6 MARKET ANALYSIS BY AGE
6.1 World Omalizumab Monoclonal Antibody Biosimilars Market Size Overview by Age: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Age
6.2.1 For Adults
6.2.2 For Teenagers
6.2.3 For Children
6.3 Market Segment by Age
6.3.1 World Omalizumab Monoclonal Antibody Biosimilars Production by Age (2021-2032)
6.3.2 World Omalizumab Monoclonal Antibody Biosimilars Production Value by Age (2021-2032)
6.3.3 World Omalizumab Monoclonal Antibody Biosimilars Average Price by Age (2021-2032)
7 MARKET ANALYSIS BY FREQUENCY
7.1 World Omalizumab Monoclonal Antibody Biosimilars Market Size Overview by Frequency: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Frequency
7.2.1 Every 2 Weeks
7.2.2 Every 4 Weeks
7.2.3 Individualized Dosing Regimen
7.3 Market Segment by Frequency
7.3.1 World Omalizumab Monoclonal Antibody Biosimilars Production by Frequency (2021-2032)
7.3.2 World Omalizumab Monoclonal Antibody Biosimilars Production Value by Frequency (2021-2032)
7.3.3 World Omalizumab Monoclonal Antibody Biosimilars Average Price by Frequency (2021-2032)
8 MARKET ANALYSIS BY APPLICATION
8.1 World Omalizumab Monoclonal Antibody Biosimilars Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Persistent Asthma
8.2.2 Nasal Polyps
8.2.3 Chronic Idiopathic Urticaria
8.3 Market Segment by Application
8.3.1 World Omalizumab Monoclonal Antibody Biosimilars Production by Application (2021-2032)
8.3.2 World Omalizumab Monoclonal Antibody Biosimilars Production Value by Application (2021-2032)
8.3.3 World Omalizumab Monoclonal Antibody Biosimilars Average Price by Application (2021-2032)
9 COMPANY PROFILES
9.1 Roche
9.1.1 Roche Details
9.1.2 Roche Major Business
9.1.3 Roche Omalizumab Monoclonal Antibody Biosimilars Product and Services
9.1.4 Roche Omalizumab Monoclonal Antibody Biosimilars Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.1.5 Roche Recent Developments/Updates
9.1.6 Roche Competitive Strengths & Weaknesses
9.2 Novartis
9.2.1 Novartis Details
9.2.2 Novartis Major Business
9.2.3 Novartis Omalizumab Monoclonal Antibody Biosimilars Product and Services
9.2.4 Novartis Omalizumab Monoclonal Antibody Biosimilars Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.2.5 Novartis Recent Developments/Updates
9.2.6 Novartis Competitive Strengths & Weaknesses
9.3 Glenmark Pharmaceuticals
9.3.1 Glenmark Pharmaceuticals Details
9.3.2 Glenmark Pharmaceuticals Major Business
9.3.3 Glenmark Pharmaceuticals Omalizumab Monoclonal Antibody Biosimilars Product and Services
9.3.4 Glenmark Pharmaceuticals Omalizumab Monoclonal Antibody Biosimilars Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.3.5 Glenmark Pharmaceuticals Recent Developments/Updates
9.3.6 Glenmark Pharmaceuticals Competitive Strengths & Weaknesses
9.4 Selexis
9.4.1 Selexis Details
9.4.2 Selexis Major Business
9.4.3 Selexis Omalizumab Monoclonal Antibody Biosimilars Product and Services
9.4.4 Selexis Omalizumab Monoclonal Antibody Biosimilars Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.4.5 Selexis Recent Developments/Updates
9.4.6 Selexis Competitive Strengths & Weaknesses
9.5 Generium
9.5.1 Generium Details
9.5.2 Generium Major Business
9.5.3 Generium Omalizumab Monoclonal Antibody Biosimilars Product and Services
9.5.4 Generium Omalizumab Monoclonal Antibody Biosimilars Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.5.5 Generium Recent Developments/Updates
9.5.6 Generium Competitive Strengths & Weaknesses
9.6 CuraTeQ
9.6.1 CuraTeQ Details
9.6.2 CuraTeQ Major Business
9.6.3 CuraTeQ Omalizumab Monoclonal Antibody Biosimilars Product and Services
9.6.4 CuraTeQ Omalizumab Monoclonal Antibody Biosimilars Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.6.5 CuraTeQ Recent Developments/Updates
9.6.6 CuraTeQ Competitive Strengths & Weaknesses
9.7 Celltrion Healthcare
9.7.1 Celltrion Healthcare Details
9.7.2 Celltrion Healthcare Major Business
9.7.3 Celltrion Healthcare Omalizumab Monoclonal Antibody Biosimilars Product and Services
9.7.4 Celltrion Healthcare Omalizumab Monoclonal Antibody Biosimilars Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.7.5 Celltrion Healthcare Recent Developments/Updates
9.7.6 Celltrion Healthcare Competitive Strengths & Weaknesses
9.8 Alvotech
9.8.1 Alvotech Details
9.8.2 Alvotech Major Business
9.8.3 Alvotech Omalizumab Monoclonal Antibody Biosimilars Product and Services
9.8.4 Alvotech Omalizumab Monoclonal Antibody Biosimilars Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.8.5 Alvotech Recent Developments/Updates
9.8.6 Alvotech Competitive Strengths & Weaknesses
9.9 BiosanaPharma
9.9.1 BiosanaPharma Details
9.9.2 BiosanaPharma Major Business
9.9.3 BiosanaPharma Omalizumab Monoclonal Antibody Biosimilars Product and Services
9.9.4 BiosanaPharma Omalizumab Monoclonal Antibody Biosimilars Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.9.5 BiosanaPharma Recent Developments/Updates
9.9.6 BiosanaPharma Competitive Strengths & Weaknesses
9.10 Mabpharm
9.10.1 Mabpharm Details
9.10.2 Mabpharm Major Business
9.10.3 Mabpharm Omalizumab Monoclonal Antibody Biosimilars Product and Services
9.10.4 Mabpharm Omalizumab Monoclonal Antibody Biosimilars Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.10.5 Mabpharm Recent Developments/Updates
9.10.6 Mabpharm Competitive Strengths & Weaknesses
9.11 CSPC Pharmaceutical Group
9.11.1 CSPC Pharmaceutical Group Details
9.11.2 CSPC Pharmaceutical Group Major Business
9.11.3 CSPC Pharmaceutical Group Omalizumab Monoclonal Antibody Biosimilars Product and Services
9.11.4 CSPC Pharmaceutical Group Omalizumab Monoclonal Antibody Biosimilars Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.11.5 CSPC Pharmaceutical Group Recent Developments/Updates
9.11.6 CSPC Pharmaceutical Group Competitive Strengths & Weaknesses
9.12 Biomabs
9.12.1 Biomabs Details
9.12.2 Biomabs Major Business
9.12.3 Biomabs Omalizumab Monoclonal Antibody Biosimilars Product and Services
9.12.4 Biomabs Omalizumab Monoclonal Antibody Biosimilars Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.12.5 Biomabs Recent Developments/Updates
9.12.6 Biomabs Competitive Strengths & Weaknesses
9.13 HisunPharm
9.13.1 HisunPharm Details
9.13.2 HisunPharm Major Business
9.13.3 HisunPharm Omalizumab Monoclonal Antibody Biosimilars Product and Services
9.13.4 HisunPharm Omalizumab Monoclonal Antibody Biosimilars Production, Price, Value, Gross Margin and Market Share (2021-2026)
9.13.5 HisunPharm Recent Developments/Updates
9.13.6 HisunPharm Competitive Strengths & Weaknesses
10 INDUSTRY CHAIN ANALYSIS
10.1 Omalizumab Monoclonal Antibody Biosimilars Industry Chain
10.2 Omalizumab Monoclonal Antibody Biosimilars Upstream Analysis
10.2.1 Omalizumab Monoclonal Antibody Biosimilars Core Raw Materials
10.2.2 Main Manufacturers of Omalizumab Monoclonal Antibody Biosimilars Core Raw Materials
10.3 Midstream Analysis
10.4 Downstream Analysis
10.5 Omalizumab Monoclonal Antibody Biosimilars Production Mode
10.6 Omalizumab Monoclonal Antibody Biosimilars Procurement Model
10.7 Omalizumab Monoclonal Antibody Biosimilars Industry Sales Model and Sales Channels
10.7.1 Omalizumab Monoclonal Antibody Biosimilars Sales Model
10.7.2 Omalizumab Monoclonal Antibody Biosimilars Typical Distributors
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
LIST OF TABLES
Table 1. World Omalizumab Monoclonal Antibody Biosimilars Production Value by Region (2021, 2025 and 2032) & (USD Million)
Table 2. World Omalizumab Monoclonal Antibody Biosimilars Production Value by Region (2021-2026) & (USD Million)
Table 3. World Omalizumab Monoclonal Antibody Biosimilars Production Value by Region (2027-2032) & (USD Million)
Table 4. World Omalizumab Monoclonal Antibody Biosimilars Production Value Market Share by Region (2021-2026)
Table 5. World Omalizumab Monoclonal Antibody Biosimilars Production Value Market Share by Region (2027-2032)
Table 6. World Omalizumab Monoclonal Antibody Biosimilars Production by Region (2021-2026) & (K Dose)
Table 7. World Omalizumab Monoclonal Antibody Biosimilars Production by Region (2027-2032) & (K Dose)
Table 8. World Omalizumab Monoclonal Antibody Biosimilars Production Market Share by Region (2021-2026)
Table 9. World Omalizumab Monoclonal Antibody Biosimilars Production Market Share by Region (2027-2032)
Table 10. World Omalizumab Monoclonal Antibody Biosimilars Average Price by Region (2021-2026) & (US$/Dose)
Table 11. World Omalizumab Monoclonal Antibody Biosimilars Average Price by Region (2027-2032) & (US$/Dose)
Table 12. Omalizumab Monoclonal Antibody Biosimilars Major Market Trends
Table 13. World Omalizumab Monoclonal Antibody Biosimilars Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (K Dose)
Table 14. World Omalizumab Monoclonal Antibody Biosimilars Consumption by Region (2021-2026) & (K Dose)
Table 15. World Omalizumab Monoclonal Antibody Biosimilars Consumption Forecast by Region (2027-2032) & (K Dose)
Table 16. World Omalizumab Monoclonal Antibody Biosimilars Production Value by Manufacturer (2021-2026) & (USD Million)
Table 17. Production Value Market Share of Key Omalizumab Monoclonal Antibody Biosimilars Producers in 2025
Table 18. World Omalizumab Monoclonal Antibody Biosimilars Production by Manufacturer (2021-2026) & (K Dose)
Table 19. Production Market Share of Key Omalizumab Monoclonal Antibody Biosimilars Producers in 2025
Table 20. World Omalizumab Monoclonal Antibody Biosimilars Average Price by Manufacturer (2021-2026) & (US$/Dose)
Table 21. Global Omalizumab Monoclonal Antibody Biosimilars Company Evaluation Quadrant
Table 22. World Omalizumab Monoclonal Antibody Biosimilars Industry Rank of Major Manufacturers, Based on Production Value in 2025
Table 23. Head Office and Omalizumab Monoclonal Antibody Biosimilars Production Site of Key Manufacturer
Table 24. Omalizumab Monoclonal Antibody Biosimilars Market: Company Product Type Footprint
Table 25. Omalizumab Monoclonal Antibody Biosimilars Market: Company Product Application Footprint
Table 26. Omalizumab Monoclonal Antibody Biosimilars Competitive Factors
Table 27. Omalizumab Monoclonal Antibody Biosimilars New Entrant and Capacity Expansion Plans
Table 28. Omalizumab Monoclonal Antibody Biosimilars Mergers & Acquisitions Activity
Table 29. United States VS China Omalizumab Monoclonal Antibody Biosimilars Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 30. United States VS China Omalizumab Monoclonal Antibody Biosimilars Production Comparison, (2021 & 2025 & 2032) & (K Dose)
Table 31. United States VS China Omalizumab Monoclonal Antibody Biosimilars Consumption Comparison, (2021 & 2025 & 2032) & (K Dose)
Table 32. United States Based Omalizumab Monoclonal Antibody Biosimilars Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Omalizumab Monoclonal Antibody Biosimilars Production Value, (2021-2026) & (USD Million)
Table 34. United States Based Manufacturers Omalizumab Monoclonal Antibody Biosimilars Production Value Market Share (2021-2026)
Table 35. United States Based Manufacturers Omalizumab Monoclonal Antibody Biosimilars Production (2021-2026) & (K Dose)
Table 36. United States Based Manufacturers Omalizumab Monoclonal Antibody Biosimilars Production Market Share (2021-2026)
Table 37. China Based Omalizumab Monoclonal Antibody Biosimilars Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Omalizumab Monoclonal Antibody Biosimilars Production Value, (2021-2026) & (USD Million)
Table 39. China Based Manufacturers Omalizumab Monoclonal Antibody Biosimilars Production Value Market Share (2021-2026)
Table 40. China Based Manufacturers Omalizumab Monoclonal Antibody Biosimilars Production, (2021-2026) & (K Dose)
Table 41. China Based Manufacturers Omalizumab Monoclonal Antibody Biosimilars Production Market Share (2021-2026)
Table 42. Rest of World Based Omalizumab Monoclonal Antibody Biosimilars Manufacturers, Headquarters and Production Site (State, Country)
Table 43. Rest of World Based Manufacturers Omalizumab Monoclonal Antibody Biosimilars Production Value, (2021-2026) & (USD Million)
Table 44. Rest of World Based Manufacturers Omalizumab Monoclonal Antibody Biosimilars Production Value Market Share (2021-2026)
Table 45. Rest of World Based Manufacturers Omalizumab Monoclonal Antibody Biosimilars Production, (2021-2026) & (K Dose)
Table 46. Rest of World Based Manufacturers Omalizumab Monoclonal Antibody Biosimilars Production Market Share (2021-2026)
Table 47. World Omalizumab Monoclonal Antibody Biosimilars Production Value by Type, (USD Million), 2021 & 2025 & 2032
Table 48. World Omalizumab Monoclonal Antibody Biosimilars Production by Type (2021-2026) & (K Dose)
Table 49. World Omalizumab Monoclonal Antibody Biosimilars Production by Type (2027-2032) & (K Dose)
Table 50. World Omalizumab Monoclonal Antibody Biosimilars Production Value by Type (2021-2026) & (USD Million)
Table 51. World Omalizumab Monoclonal Antibody Biosimilars Production Value by Type (2027-2032) & (USD Million)
Table 52. World Omalizumab Monoclonal Antibody Biosimilars Average Price by Type (2021-2026) & (US$/Dose)
Table 53. World Omalizumab Monoclonal Antibody Biosimilars Average Price by Type (2027-2032) & (US$/Dose)
Table 54. World Omalizumab Monoclonal Antibody Biosimilars Production Value by Age, (USD Million), 2021 & 2025 & 2032
Table 55. World Omalizumab Monoclonal Antibody Biosimilars Production by Age (2021-2026) & (K Dose)
Table 56. World Omalizumab Monoclonal Antibody Biosimilars Production by Age (2027-2032) & (K Dose)
Table 57. World Omalizumab Monoclonal Antibody Biosimilars Production Value by Age (2021-2026) & (USD Million)
Table 58. World Omalizumab Monoclonal Antibody Biosimilars Production Value by Age (2027-2032) & (USD Million)
Table 59. World Omalizumab Monoclonal Antibody Biosimilars Average Price by Age (2021-2026) & (US$/Dose)
Table 60. World Omalizumab Monoclonal Antibody Biosimilars Average Price by Age (2027-2032) & (US$/Dose)
Table 61. World Omalizumab Monoclonal Antibody Biosimilars Production Value by Frequency, (USD Million), 2021 & 2025 & 2032
Table 62. World Omalizumab Monoclonal Antibody Biosimilars Production by Frequency (2021-2026) & (K Dose)
Table 63. World Omalizumab Monoclonal Antibody Biosimilars Production by Frequency (2027-2032) & (K Dose)
Table 64. World Omalizumab Monoclonal Antibody Biosimilars Production Value by Frequency (2021-2026) & (USD Million)
Table 65. World Omalizumab Monoclonal Antibody Biosimilars Production Value by Frequency (2027-2032) & (USD Million)
Table 66. World Omalizumab Monoclonal Antibody Biosimilars Average Price by Frequency (2021-2026) & (US$/Dose)
Table 67. World Omalizumab Monoclonal Antibody Biosimilars Average Price by Frequency (2027-2032) & (US$/Dose)
Table 68. World Omalizumab Monoclonal Antibody Biosimilars Production Value by Application, (USD Million), 2021 & 2025 & 2032
Table 69. World Omalizumab Monoclonal Antibody Biosimilars Production by Application (2021-2026) & (K Dose)
Table 70. World Omalizumab Monoclonal Antibody Biosimilars Production by Application (2027-2032) & (K Dose)
Table 71. World Omalizumab Monoclonal Antibody Biosimilars Production Value by Application (2021-2026) & (USD Million)
Table 72. World Omalizumab Monoclonal Antibody Biosimilars Production Value by Application (2027-2032) & (USD Million)
Table 73. World Omalizumab Monoclonal Antibody Biosimilars Average Price by Application (2021-2026) & (US$/Dose)
Table 74. World Omalizumab Monoclonal Antibody Biosimilars Average Price by Application (2027-2032) & (US$/Dose)
Table 75. Roche Basic Information, Manufacturing Base and Competitors
Table 76. Roche Major Business
Table 77. Roche Omalizumab Monoclonal Antibody Biosimilars Product and Services
Table 78. Roche Omalizumab Monoclonal Antibody Biosimilars Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 79. Roche Recent Developments/Updates
Table 80. Roche Competitive Strengths & Weaknesses
Table 81. Novartis Basic Information, Manufacturing Base and Competitors
Table 82. Novartis Major Business
Table 83. Novartis Omalizumab Monoclonal Antibody Biosimilars Product and Services
Table 84. Novartis Omalizumab Monoclonal Antibody Biosimilars Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 85. Novartis Recent Developments/Updates
Table 86. Novartis Competitive Strengths & Weaknesses
Table 87. Glenmark Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 88. Glenmark Pharmaceuticals Major Business
Table 89. Glenmark Pharmaceuticals Omalizumab Monoclonal Antibody Biosimilars Product and Services
Table 90. Glenmark Pharmaceuticals Omalizumab Monoclonal Antibody Biosimilars Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 91. Glenmark Pharmaceuticals Recent Developments/Updates
Table 92. Glenmark Pharmaceuticals Competitive Strengths & Weaknesses
Table 93. Selexis Basic Information, Manufacturing Base and Competitors
Table 94. Selexis Major Business
Table 95. Selexis Omalizumab Monoclonal Antibody Biosimilars Product and Services
Table 96. Selexis Omalizumab Monoclonal Antibody Biosimilars Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 97. Selexis Recent Developments/Updates
Table 98. Selexis Competitive Strengths & Weaknesses
Table 99. Generium Basic Information, Manufacturing Base and Competitors
Table 100. Generium Major Business
Table 101. Generium Omalizumab Monoclonal Antibody Biosimilars Product and Services
Table 102. Generium Omalizumab Monoclonal Antibody Biosimilars Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 103. Generium Recent Developments/Updates
Table 104. Generium Competitive Strengths & Weaknesses
Table 105. CuraTeQ Basic Information, Manufacturing Base and Competitors
Table 106. CuraTeQ Major Business
Table 107. CuraTeQ Omalizumab Monoclonal Antibody Biosimilars Product and Services
Table 108. CuraTeQ Omalizumab Monoclonal Antibody Biosimilars Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 109. CuraTeQ Recent Developments/Updates
Table 110. CuraTeQ Competitive Strengths & Weaknesses
Table 111. Celltrion Healthcare Basic Information, Manufacturing Base and Competitors
Table 112. Celltrion Healthcare Major Business
Table 113. Celltrion Healthcare Omalizumab Monoclonal Antibody Biosimilars Product and Services
Table 114. Celltrion Healthcare Omalizumab Monoclonal Antibody Biosimilars Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 115. Celltrion Healthcare Recent Developments/Updates
Table 116. Celltrion Healthcare Competitive Strengths & Weaknesses
Table 117. Alvotech Basic Information, Manufacturing Base and Competitors
Table 118. Alvotech Major Business
Table 119. Alvotech Omalizumab Monoclonal Antibody Biosimilars Product and Services
Table 120. Alvotech Omalizumab Monoclonal Antibody Biosimilars Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 121. Alvotech Recent Developments/Updates
Table 122. Alvotech Competitive Strengths & Weaknesses
Table 123. BiosanaPharma Basic Information, Manufacturing Base and Competitors
Table 124. BiosanaPharma Major Business
Table 125. BiosanaPharma Omalizumab Monoclonal Antibody Biosimilars Product and Services
Table 126. BiosanaPharma Omalizumab Monoclonal Antibody Biosimilars Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 127. BiosanaPharma Recent Developments/Updates
Table 128. BiosanaPharma Competitive Strengths & Weaknesses
Table 129. Mabpharm Basic Information, Manufacturing Base and Competitors
Table 130. Mabpharm Major Business
Table 131. Mabpharm Omalizumab Monoclonal Antibody Biosimilars Product and Services
Table 132. Mabpharm Omalizumab Monoclonal Antibody Biosimilars Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 133. Mabpharm Recent Developments/Updates
Table 134. Mabpharm Competitive Strengths & Weaknesses
Table 135. CSPC Pharmaceutical Group Basic Information, Manufacturing Base and Competitors
Table 136. CSPC Pharmaceutical Group Major Business
Table 137. CSPC Pharmaceutical Group Omalizumab Monoclonal Antibody Biosimilars Product and Services
Table 138. CSPC Pharmaceutical Group Omalizumab Monoclonal Antibody Biosimilars Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 139. CSPC Pharmaceutical Group Recent Developments/Updates
Table 140. CSPC Pharmaceutical Group Competitive Strengths & Weaknesses
Table 141. Biomabs Basic Information, Manufacturing Base and Competitors
Table 142. Biomabs Major Business
Table 143. Biomabs Omalizumab Monoclonal Antibody Biosimilars Product and Services
Table 144. Biomabs Omalizumab Monoclonal Antibody Biosimilars Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 145. Biomabs Recent Developments/Updates
Table 146. Biomabs Competitive Strengths & Weaknesses
Table 147. HisunPharm Basic Information, Manufacturing Base and Competitors
Table 148. HisunPharm Major Business
Table 149. HisunPharm Omalizumab Monoclonal Antibody Biosimilars Product and Services
Table 150. HisunPharm Omalizumab Monoclonal Antibody Biosimilars Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 151. HisunPharm Recent Developments/Updates
Table 152. HisunPharm Competitive Strengths & Weaknesses
Table 153. Global Key Players of Omalizumab Monoclonal Antibody Biosimilars Upstream (Raw Materials)
Table 154. Global Omalizumab Monoclonal Antibody Biosimilars Typical Customers
Table 155. Omalizumab Monoclonal Antibody Biosimilars Typical Distributors
Table 1. World Omalizumab Monoclonal Antibody Biosimilars Production Value by Region (2021, 2025 and 2032) & (USD Million)
Table 2. World Omalizumab Monoclonal Antibody Biosimilars Production Value by Region (2021-2026) & (USD Million)
Table 3. World Omalizumab Monoclonal Antibody Biosimilars Production Value by Region (2027-2032) & (USD Million)
Table 4. World Omalizumab Monoclonal Antibody Biosimilars Production Value Market Share by Region (2021-2026)
Table 5. World Omalizumab Monoclonal Antibody Biosimilars Production Value Market Share by Region (2027-2032)
Table 6. World Omalizumab Monoclonal Antibody Biosimilars Production by Region (2021-2026) & (K Dose)
Table 7. World Omalizumab Monoclonal Antibody Biosimilars Production by Region (2027-2032) & (K Dose)
Table 8. World Omalizumab Monoclonal Antibody Biosimilars Production Market Share by Region (2021-2026)
Table 9. World Omalizumab Monoclonal Antibody Biosimilars Production Market Share by Region (2027-2032)
Table 10. World Omalizumab Monoclonal Antibody Biosimilars Average Price by Region (2021-2026) & (US$/Dose)
Table 11. World Omalizumab Monoclonal Antibody Biosimilars Average Price by Region (2027-2032) & (US$/Dose)
Table 12. Omalizumab Monoclonal Antibody Biosimilars Major Market Trends
Table 13. World Omalizumab Monoclonal Antibody Biosimilars Consumption Growth Rate Forecast by Region (2021 & 2025 & 2032) & (K Dose)
Table 14. World Omalizumab Monoclonal Antibody Biosimilars Consumption by Region (2021-2026) & (K Dose)
Table 15. World Omalizumab Monoclonal Antibody Biosimilars Consumption Forecast by Region (2027-2032) & (K Dose)
Table 16. World Omalizumab Monoclonal Antibody Biosimilars Production Value by Manufacturer (2021-2026) & (USD Million)
Table 17. Production Value Market Share of Key Omalizumab Monoclonal Antibody Biosimilars Producers in 2025
Table 18. World Omalizumab Monoclonal Antibody Biosimilars Production by Manufacturer (2021-2026) & (K Dose)
Table 19. Production Market Share of Key Omalizumab Monoclonal Antibody Biosimilars Producers in 2025
Table 20. World Omalizumab Monoclonal Antibody Biosimilars Average Price by Manufacturer (2021-2026) & (US$/Dose)
Table 21. Global Omalizumab Monoclonal Antibody Biosimilars Company Evaluation Quadrant
Table 22. World Omalizumab Monoclonal Antibody Biosimilars Industry Rank of Major Manufacturers, Based on Production Value in 2025
Table 23. Head Office and Omalizumab Monoclonal Antibody Biosimilars Production Site of Key Manufacturer
Table 24. Omalizumab Monoclonal Antibody Biosimilars Market: Company Product Type Footprint
Table 25. Omalizumab Monoclonal Antibody Biosimilars Market: Company Product Application Footprint
Table 26. Omalizumab Monoclonal Antibody Biosimilars Competitive Factors
Table 27. Omalizumab Monoclonal Antibody Biosimilars New Entrant and Capacity Expansion Plans
Table 28. Omalizumab Monoclonal Antibody Biosimilars Mergers & Acquisitions Activity
Table 29. United States VS China Omalizumab Monoclonal Antibody Biosimilars Production Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 30. United States VS China Omalizumab Monoclonal Antibody Biosimilars Production Comparison, (2021 & 2025 & 2032) & (K Dose)
Table 31. United States VS China Omalizumab Monoclonal Antibody Biosimilars Consumption Comparison, (2021 & 2025 & 2032) & (K Dose)
Table 32. United States Based Omalizumab Monoclonal Antibody Biosimilars Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Omalizumab Monoclonal Antibody Biosimilars Production Value, (2021-2026) & (USD Million)
Table 34. United States Based Manufacturers Omalizumab Monoclonal Antibody Biosimilars Production Value Market Share (2021-2026)
Table 35. United States Based Manufacturers Omalizumab Monoclonal Antibody Biosimilars Production (2021-2026) & (K Dose)
Table 36. United States Based Manufacturers Omalizumab Monoclonal Antibody Biosimilars Production Market Share (2021-2026)
Table 37. China Based Omalizumab Monoclonal Antibody Biosimilars Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Omalizumab Monoclonal Antibody Biosimilars Production Value, (2021-2026) & (USD Million)
Table 39. China Based Manufacturers Omalizumab Monoclonal Antibody Biosimilars Production Value Market Share (2021-2026)
Table 40. China Based Manufacturers Omalizumab Monoclonal Antibody Biosimilars Production, (2021-2026) & (K Dose)
Table 41. China Based Manufacturers Omalizumab Monoclonal Antibody Biosimilars Production Market Share (2021-2026)
Table 42. Rest of World Based Omalizumab Monoclonal Antibody Biosimilars Manufacturers, Headquarters and Production Site (State, Country)
Table 43. Rest of World Based Manufacturers Omalizumab Monoclonal Antibody Biosimilars Production Value, (2021-2026) & (USD Million)
Table 44. Rest of World Based Manufacturers Omalizumab Monoclonal Antibody Biosimilars Production Value Market Share (2021-2026)
Table 45. Rest of World Based Manufacturers Omalizumab Monoclonal Antibody Biosimilars Production, (2021-2026) & (K Dose)
Table 46. Rest of World Based Manufacturers Omalizumab Monoclonal Antibody Biosimilars Production Market Share (2021-2026)
Table 47. World Omalizumab Monoclonal Antibody Biosimilars Production Value by Type, (USD Million), 2021 & 2025 & 2032
Table 48. World Omalizumab Monoclonal Antibody Biosimilars Production by Type (2021-2026) & (K Dose)
Table 49. World Omalizumab Monoclonal Antibody Biosimilars Production by Type (2027-2032) & (K Dose)
Table 50. World Omalizumab Monoclonal Antibody Biosimilars Production Value by Type (2021-2026) & (USD Million)
Table 51. World Omalizumab Monoclonal Antibody Biosimilars Production Value by Type (2027-2032) & (USD Million)
Table 52. World Omalizumab Monoclonal Antibody Biosimilars Average Price by Type (2021-2026) & (US$/Dose)
Table 53. World Omalizumab Monoclonal Antibody Biosimilars Average Price by Type (2027-2032) & (US$/Dose)
Table 54. World Omalizumab Monoclonal Antibody Biosimilars Production Value by Age, (USD Million), 2021 & 2025 & 2032
Table 55. World Omalizumab Monoclonal Antibody Biosimilars Production by Age (2021-2026) & (K Dose)
Table 56. World Omalizumab Monoclonal Antibody Biosimilars Production by Age (2027-2032) & (K Dose)
Table 57. World Omalizumab Monoclonal Antibody Biosimilars Production Value by Age (2021-2026) & (USD Million)
Table 58. World Omalizumab Monoclonal Antibody Biosimilars Production Value by Age (2027-2032) & (USD Million)
Table 59. World Omalizumab Monoclonal Antibody Biosimilars Average Price by Age (2021-2026) & (US$/Dose)
Table 60. World Omalizumab Monoclonal Antibody Biosimilars Average Price by Age (2027-2032) & (US$/Dose)
Table 61. World Omalizumab Monoclonal Antibody Biosimilars Production Value by Frequency, (USD Million), 2021 & 2025 & 2032
Table 62. World Omalizumab Monoclonal Antibody Biosimilars Production by Frequency (2021-2026) & (K Dose)
Table 63. World Omalizumab Monoclonal Antibody Biosimilars Production by Frequency (2027-2032) & (K Dose)
Table 64. World Omalizumab Monoclonal Antibody Biosimilars Production Value by Frequency (2021-2026) & (USD Million)
Table 65. World Omalizumab Monoclonal Antibody Biosimilars Production Value by Frequency (2027-2032) & (USD Million)
Table 66. World Omalizumab Monoclonal Antibody Biosimilars Average Price by Frequency (2021-2026) & (US$/Dose)
Table 67. World Omalizumab Monoclonal Antibody Biosimilars Average Price by Frequency (2027-2032) & (US$/Dose)
Table 68. World Omalizumab Monoclonal Antibody Biosimilars Production Value by Application, (USD Million), 2021 & 2025 & 2032
Table 69. World Omalizumab Monoclonal Antibody Biosimilars Production by Application (2021-2026) & (K Dose)
Table 70. World Omalizumab Monoclonal Antibody Biosimilars Production by Application (2027-2032) & (K Dose)
Table 71. World Omalizumab Monoclonal Antibody Biosimilars Production Value by Application (2021-2026) & (USD Million)
Table 72. World Omalizumab Monoclonal Antibody Biosimilars Production Value by Application (2027-2032) & (USD Million)
Table 73. World Omalizumab Monoclonal Antibody Biosimilars Average Price by Application (2021-2026) & (US$/Dose)
Table 74. World Omalizumab Monoclonal Antibody Biosimilars Average Price by Application (2027-2032) & (US$/Dose)
Table 75. Roche Basic Information, Manufacturing Base and Competitors
Table 76. Roche Major Business
Table 77. Roche Omalizumab Monoclonal Antibody Biosimilars Product and Services
Table 78. Roche Omalizumab Monoclonal Antibody Biosimilars Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 79. Roche Recent Developments/Updates
Table 80. Roche Competitive Strengths & Weaknesses
Table 81. Novartis Basic Information, Manufacturing Base and Competitors
Table 82. Novartis Major Business
Table 83. Novartis Omalizumab Monoclonal Antibody Biosimilars Product and Services
Table 84. Novartis Omalizumab Monoclonal Antibody Biosimilars Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 85. Novartis Recent Developments/Updates
Table 86. Novartis Competitive Strengths & Weaknesses
Table 87. Glenmark Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 88. Glenmark Pharmaceuticals Major Business
Table 89. Glenmark Pharmaceuticals Omalizumab Monoclonal Antibody Biosimilars Product and Services
Table 90. Glenmark Pharmaceuticals Omalizumab Monoclonal Antibody Biosimilars Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 91. Glenmark Pharmaceuticals Recent Developments/Updates
Table 92. Glenmark Pharmaceuticals Competitive Strengths & Weaknesses
Table 93. Selexis Basic Information, Manufacturing Base and Competitors
Table 94. Selexis Major Business
Table 95. Selexis Omalizumab Monoclonal Antibody Biosimilars Product and Services
Table 96. Selexis Omalizumab Monoclonal Antibody Biosimilars Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 97. Selexis Recent Developments/Updates
Table 98. Selexis Competitive Strengths & Weaknesses
Table 99. Generium Basic Information, Manufacturing Base and Competitors
Table 100. Generium Major Business
Table 101. Generium Omalizumab Monoclonal Antibody Biosimilars Product and Services
Table 102. Generium Omalizumab Monoclonal Antibody Biosimilars Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 103. Generium Recent Developments/Updates
Table 104. Generium Competitive Strengths & Weaknesses
Table 105. CuraTeQ Basic Information, Manufacturing Base and Competitors
Table 106. CuraTeQ Major Business
Table 107. CuraTeQ Omalizumab Monoclonal Antibody Biosimilars Product and Services
Table 108. CuraTeQ Omalizumab Monoclonal Antibody Biosimilars Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 109. CuraTeQ Recent Developments/Updates
Table 110. CuraTeQ Competitive Strengths & Weaknesses
Table 111. Celltrion Healthcare Basic Information, Manufacturing Base and Competitors
Table 112. Celltrion Healthcare Major Business
Table 113. Celltrion Healthcare Omalizumab Monoclonal Antibody Biosimilars Product and Services
Table 114. Celltrion Healthcare Omalizumab Monoclonal Antibody Biosimilars Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 115. Celltrion Healthcare Recent Developments/Updates
Table 116. Celltrion Healthcare Competitive Strengths & Weaknesses
Table 117. Alvotech Basic Information, Manufacturing Base and Competitors
Table 118. Alvotech Major Business
Table 119. Alvotech Omalizumab Monoclonal Antibody Biosimilars Product and Services
Table 120. Alvotech Omalizumab Monoclonal Antibody Biosimilars Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 121. Alvotech Recent Developments/Updates
Table 122. Alvotech Competitive Strengths & Weaknesses
Table 123. BiosanaPharma Basic Information, Manufacturing Base and Competitors
Table 124. BiosanaPharma Major Business
Table 125. BiosanaPharma Omalizumab Monoclonal Antibody Biosimilars Product and Services
Table 126. BiosanaPharma Omalizumab Monoclonal Antibody Biosimilars Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 127. BiosanaPharma Recent Developments/Updates
Table 128. BiosanaPharma Competitive Strengths & Weaknesses
Table 129. Mabpharm Basic Information, Manufacturing Base and Competitors
Table 130. Mabpharm Major Business
Table 131. Mabpharm Omalizumab Monoclonal Antibody Biosimilars Product and Services
Table 132. Mabpharm Omalizumab Monoclonal Antibody Biosimilars Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 133. Mabpharm Recent Developments/Updates
Table 134. Mabpharm Competitive Strengths & Weaknesses
Table 135. CSPC Pharmaceutical Group Basic Information, Manufacturing Base and Competitors
Table 136. CSPC Pharmaceutical Group Major Business
Table 137. CSPC Pharmaceutical Group Omalizumab Monoclonal Antibody Biosimilars Product and Services
Table 138. CSPC Pharmaceutical Group Omalizumab Monoclonal Antibody Biosimilars Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 139. CSPC Pharmaceutical Group Recent Developments/Updates
Table 140. CSPC Pharmaceutical Group Competitive Strengths & Weaknesses
Table 141. Biomabs Basic Information, Manufacturing Base and Competitors
Table 142. Biomabs Major Business
Table 143. Biomabs Omalizumab Monoclonal Antibody Biosimilars Product and Services
Table 144. Biomabs Omalizumab Monoclonal Antibody Biosimilars Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 145. Biomabs Recent Developments/Updates
Table 146. Biomabs Competitive Strengths & Weaknesses
Table 147. HisunPharm Basic Information, Manufacturing Base and Competitors
Table 148. HisunPharm Major Business
Table 149. HisunPharm Omalizumab Monoclonal Antibody Biosimilars Product and Services
Table 150. HisunPharm Omalizumab Monoclonal Antibody Biosimilars Production (K Dose), Price (US$/Dose), Production Value (USD Million), Gross Margin and Market Share (2021-2026)
Table 151. HisunPharm Recent Developments/Updates
Table 152. HisunPharm Competitive Strengths & Weaknesses
Table 153. Global Key Players of Omalizumab Monoclonal Antibody Biosimilars Upstream (Raw Materials)
Table 154. Global Omalizumab Monoclonal Antibody Biosimilars Typical Customers
Table 155. Omalizumab Monoclonal Antibody Biosimilars Typical Distributors
LIST OF FIGURES
Figure 1. Omalizumab Monoclonal Antibody Biosimilars Picture
Figure 2. World Omalizumab Monoclonal Antibody Biosimilars Production Value: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Omalizumab Monoclonal Antibody Biosimilars Production Value and Forecast (2021-2032) & (USD Million)
Figure 4. World Omalizumab Monoclonal Antibody Biosimilars Production (2021-2032) & (K Dose)
Figure 5. World Omalizumab Monoclonal Antibody Biosimilars Average Price (2021-2032) & (US$/Dose)
Figure 6. World Omalizumab Monoclonal Antibody Biosimilars Production Value Market Share by Region (2021-2032)
Figure 7. World Omalizumab Monoclonal Antibody Biosimilars Production Market Share by Region (2021-2032)
Figure 8. North America Omalizumab Monoclonal Antibody Biosimilars Production (2021-2032) & (K Dose)
Figure 9. Europe Omalizumab Monoclonal Antibody Biosimilars Production (2021-2032) & (K Dose)
Figure 10. China Omalizumab Monoclonal Antibody Biosimilars Production (2021-2032) & (K Dose)
Figure 11. Japan Omalizumab Monoclonal Antibody Biosimilars Production (2021-2032) & (K Dose)
Figure 12. Omalizumab Monoclonal Antibody Biosimilars Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Omalizumab Monoclonal Antibody Biosimilars Consumption (2021-2032) & (K Dose)
Figure 15. World Omalizumab Monoclonal Antibody Biosimilars Consumption Market Share by Region (2021-2032)
Figure 16. United States Omalizumab Monoclonal Antibody Biosimilars Consumption (2021-2032) & (K Dose)
Figure 17. China Omalizumab Monoclonal Antibody Biosimilars Consumption (2021-2032) & (K Dose)
Figure 18. Europe Omalizumab Monoclonal Antibody Biosimilars Consumption (2021-2032) & (K Dose)
Figure 19. Japan Omalizumab Monoclonal Antibody Biosimilars Consumption (2021-2032) & (K Dose)
Figure 20. South Korea Omalizumab Monoclonal Antibody Biosimilars Consumption (2021-2032) & (K Dose)
Figure 21. ASEAN Omalizumab Monoclonal Antibody Biosimilars Consumption (2021-2032) & (K Dose)
Figure 22. India Omalizumab Monoclonal Antibody Biosimilars Consumption (2021-2032) & (K Dose)
Figure 23. Producer Shipments of Omalizumab Monoclonal Antibody Biosimilars by Manufacturer Revenue ($MM) and Market Share (%): 2025
Figure 24. Global Four-firm Concentration Ratios (CR4) for Omalizumab Monoclonal Antibody Biosimilars Markets in 2025
Figure 25. Global Four-firm Concentration Ratios (CR8) for Omalizumab Monoclonal Antibody Biosimilars Markets in 2025
Figure 26. United States VS China: Omalizumab Monoclonal Antibody Biosimilars Production Value Market Share Comparison (2021 & 2025 & 2032)
Figure 27. United States VS China: Omalizumab Monoclonal Antibody Biosimilars Production Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Omalizumab Monoclonal Antibody Biosimilars Consumption Market Share Comparison (2021 & 2025 & 2032)
Figure 29. United States Based Manufacturers Omalizumab Monoclonal Antibody Biosimilars Production Market Share 2025
Figure 30. China Based Manufacturers Omalizumab Monoclonal Antibody Biosimilars Production Market Share 2025
Figure 31. Rest of World Based Manufacturers Omalizumab Monoclonal Antibody Biosimilars Production Market Share 2025
Figure 32. World Omalizumab Monoclonal Antibody Biosimilars Production Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 33. World Omalizumab Monoclonal Antibody Biosimilars Production Value Market Share by Type in 2025
Figure 34. 150 mg/mL
Figure 35. 75 mg/0.5 mL
Figure 36. World Omalizumab Monoclonal Antibody Biosimilars Production Market Share by Type (2021-2032)
Figure 37. World Omalizumab Monoclonal Antibody Biosimilars Production Value Market Share by Type (2021-2032)
Figure 38. World Omalizumab Monoclonal Antibody Biosimilars Average Price by Type (2021-2032) & (US$/Dose)
Figure 39. World Omalizumab Monoclonal Antibody Biosimilars Production Value by Age, (USD Million), 2021 & 2025 & 2032
Figure 40. World Omalizumab Monoclonal Antibody Biosimilars Production Value Market Share by Age in 2025
Figure 41. For Adults
Figure 42. For Teenagers
Figure 43. For Children
Figure 44. World Omalizumab Monoclonal Antibody Biosimilars Production Market Share by Age (2021-2032)
Figure 45. World Omalizumab Monoclonal Antibody Biosimilars Production Value Market Share by Age (2021-2032)
Figure 46. World Omalizumab Monoclonal Antibody Biosimilars Average Price by Age (2021-2032) & (US$/Dose)
Figure 47. World Omalizumab Monoclonal Antibody Biosimilars Production Value by Frequency, (USD Million), 2021 & 2025 & 2032
Figure 48. World Omalizumab Monoclonal Antibody Biosimilars Production Value Market Share by Frequency in 2025
Figure 49. Every 2 Weeks
Figure 50. Every 4 Weeks
Figure 51. Individualized Dosing Regimen
Figure 52. World Omalizumab Monoclonal Antibody Biosimilars Production Market Share by Frequency (2021-2032)
Figure 53. World Omalizumab Monoclonal Antibody Biosimilars Production Value Market Share by Frequency (2021-2032)
Figure 54. World Omalizumab Monoclonal Antibody Biosimilars Average Price by Frequency (2021-2032) & (US$/Dose)
Figure 55. World Omalizumab Monoclonal Antibody Biosimilars Production Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 56. World Omalizumab Monoclonal Antibody Biosimilars Production Value Market Share by Application in 2025
Figure 57. Persistent Asthma
Figure 58. Nasal Polyps
Figure 59. Chronic Idiopathic Urticaria
Figure 60. World Omalizumab Monoclonal Antibody Biosimilars Production Market Share by Application (2021-2032)
Figure 61. World Omalizumab Monoclonal Antibody Biosimilars Production Value Market Share by Application (2021-2032)
Figure 62. World Omalizumab Monoclonal Antibody Biosimilars Average Price by Application (2021-2032) & (US$/Dose)
Figure 63. Omalizumab Monoclonal Antibody Biosimilars Industry Chain
Figure 64. Omalizumab Monoclonal Antibody Biosimilars Procurement Model
Figure 65. Omalizumab Monoclonal Antibody Biosimilars Sales Model
Figure 66. Omalizumab Monoclonal Antibody Biosimilars Sales Channels, Direct Sales, and Distribution
Figure 67. Methodology
Figure 68. Research Process and Data Source
Figure 1. Omalizumab Monoclonal Antibody Biosimilars Picture
Figure 2. World Omalizumab Monoclonal Antibody Biosimilars Production Value: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Omalizumab Monoclonal Antibody Biosimilars Production Value and Forecast (2021-2032) & (USD Million)
Figure 4. World Omalizumab Monoclonal Antibody Biosimilars Production (2021-2032) & (K Dose)
Figure 5. World Omalizumab Monoclonal Antibody Biosimilars Average Price (2021-2032) & (US$/Dose)
Figure 6. World Omalizumab Monoclonal Antibody Biosimilars Production Value Market Share by Region (2021-2032)
Figure 7. World Omalizumab Monoclonal Antibody Biosimilars Production Market Share by Region (2021-2032)
Figure 8. North America Omalizumab Monoclonal Antibody Biosimilars Production (2021-2032) & (K Dose)
Figure 9. Europe Omalizumab Monoclonal Antibody Biosimilars Production (2021-2032) & (K Dose)
Figure 10. China Omalizumab Monoclonal Antibody Biosimilars Production (2021-2032) & (K Dose)
Figure 11. Japan Omalizumab Monoclonal Antibody Biosimilars Production (2021-2032) & (K Dose)
Figure 12. Omalizumab Monoclonal Antibody Biosimilars Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Omalizumab Monoclonal Antibody Biosimilars Consumption (2021-2032) & (K Dose)
Figure 15. World Omalizumab Monoclonal Antibody Biosimilars Consumption Market Share by Region (2021-2032)
Figure 16. United States Omalizumab Monoclonal Antibody Biosimilars Consumption (2021-2032) & (K Dose)
Figure 17. China Omalizumab Monoclonal Antibody Biosimilars Consumption (2021-2032) & (K Dose)
Figure 18. Europe Omalizumab Monoclonal Antibody Biosimilars Consumption (2021-2032) & (K Dose)
Figure 19. Japan Omalizumab Monoclonal Antibody Biosimilars Consumption (2021-2032) & (K Dose)
Figure 20. South Korea Omalizumab Monoclonal Antibody Biosimilars Consumption (2021-2032) & (K Dose)
Figure 21. ASEAN Omalizumab Monoclonal Antibody Biosimilars Consumption (2021-2032) & (K Dose)
Figure 22. India Omalizumab Monoclonal Antibody Biosimilars Consumption (2021-2032) & (K Dose)
Figure 23. Producer Shipments of Omalizumab Monoclonal Antibody Biosimilars by Manufacturer Revenue ($MM) and Market Share (%): 2025
Figure 24. Global Four-firm Concentration Ratios (CR4) for Omalizumab Monoclonal Antibody Biosimilars Markets in 2025
Figure 25. Global Four-firm Concentration Ratios (CR8) for Omalizumab Monoclonal Antibody Biosimilars Markets in 2025
Figure 26. United States VS China: Omalizumab Monoclonal Antibody Biosimilars Production Value Market Share Comparison (2021 & 2025 & 2032)
Figure 27. United States VS China: Omalizumab Monoclonal Antibody Biosimilars Production Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Omalizumab Monoclonal Antibody Biosimilars Consumption Market Share Comparison (2021 & 2025 & 2032)
Figure 29. United States Based Manufacturers Omalizumab Monoclonal Antibody Biosimilars Production Market Share 2025
Figure 30. China Based Manufacturers Omalizumab Monoclonal Antibody Biosimilars Production Market Share 2025
Figure 31. Rest of World Based Manufacturers Omalizumab Monoclonal Antibody Biosimilars Production Market Share 2025
Figure 32. World Omalizumab Monoclonal Antibody Biosimilars Production Value by Type, (USD Million), 2021 & 2025 & 2032
Figure 33. World Omalizumab Monoclonal Antibody Biosimilars Production Value Market Share by Type in 2025
Figure 34. 150 mg/mL
Figure 35. 75 mg/0.5 mL
Figure 36. World Omalizumab Monoclonal Antibody Biosimilars Production Market Share by Type (2021-2032)
Figure 37. World Omalizumab Monoclonal Antibody Biosimilars Production Value Market Share by Type (2021-2032)
Figure 38. World Omalizumab Monoclonal Antibody Biosimilars Average Price by Type (2021-2032) & (US$/Dose)
Figure 39. World Omalizumab Monoclonal Antibody Biosimilars Production Value by Age, (USD Million), 2021 & 2025 & 2032
Figure 40. World Omalizumab Monoclonal Antibody Biosimilars Production Value Market Share by Age in 2025
Figure 41. For Adults
Figure 42. For Teenagers
Figure 43. For Children
Figure 44. World Omalizumab Monoclonal Antibody Biosimilars Production Market Share by Age (2021-2032)
Figure 45. World Omalizumab Monoclonal Antibody Biosimilars Production Value Market Share by Age (2021-2032)
Figure 46. World Omalizumab Monoclonal Antibody Biosimilars Average Price by Age (2021-2032) & (US$/Dose)
Figure 47. World Omalizumab Monoclonal Antibody Biosimilars Production Value by Frequency, (USD Million), 2021 & 2025 & 2032
Figure 48. World Omalizumab Monoclonal Antibody Biosimilars Production Value Market Share by Frequency in 2025
Figure 49. Every 2 Weeks
Figure 50. Every 4 Weeks
Figure 51. Individualized Dosing Regimen
Figure 52. World Omalizumab Monoclonal Antibody Biosimilars Production Market Share by Frequency (2021-2032)
Figure 53. World Omalizumab Monoclonal Antibody Biosimilars Production Value Market Share by Frequency (2021-2032)
Figure 54. World Omalizumab Monoclonal Antibody Biosimilars Average Price by Frequency (2021-2032) & (US$/Dose)
Figure 55. World Omalizumab Monoclonal Antibody Biosimilars Production Value by Application, (USD Million), 2021 & 2025 & 2032
Figure 56. World Omalizumab Monoclonal Antibody Biosimilars Production Value Market Share by Application in 2025
Figure 57. Persistent Asthma
Figure 58. Nasal Polyps
Figure 59. Chronic Idiopathic Urticaria
Figure 60. World Omalizumab Monoclonal Antibody Biosimilars Production Market Share by Application (2021-2032)
Figure 61. World Omalizumab Monoclonal Antibody Biosimilars Production Value Market Share by Application (2021-2032)
Figure 62. World Omalizumab Monoclonal Antibody Biosimilars Average Price by Application (2021-2032) & (US$/Dose)
Figure 63. Omalizumab Monoclonal Antibody Biosimilars Industry Chain
Figure 64. Omalizumab Monoclonal Antibody Biosimilars Procurement Model
Figure 65. Omalizumab Monoclonal Antibody Biosimilars Sales Model
Figure 66. Omalizumab Monoclonal Antibody Biosimilars Sales Channels, Direct Sales, and Distribution
Figure 67. Methodology
Figure 68. Research Process and Data Source
